SLE: Novel Postulates for Therapeutic Options
نویسندگان
چکیده
منابع مشابه
Novel therapeutic options in Acute Myeloid Leukemia
Acute myeloid leukemia (AML) is a biologically complex and molecularly and clinically heterogeneous disease, and its incidence is increasing as the population ages. Cytogenetic anomalies and mutation testing remain important prognostic tools for tailoring treatment after induction therapy. Despite major advances in understanding the genetic landscape of AML and its impact on the pathophysiology...
متن کاملNovel concepts and therapeutic options for the treatment of SCHIZOPHRENIA
severe mental disorder that affects about 1% of the population in industrialised countries. The estimated cost of the disease to the American society exceeds $32 billion annually. The disease is severely incapacitating for patients in managing their lives as masterfully portrayed in the book A Beautiful Mind and the 2002 Academy Awardwinning movie with the same title1. The first symptoms of sch...
متن کاملNovel Therapeutic Options for the Treatment of Nonvalvular Atrial Fibrillation
Objective: To review the literature for the emerging oral anticoagulants, dabigatran, rivaroxaban, and apixaban currently available in the United States. Data Source: A literature review was performed in MEDLINE (1947–July 2014) using the keywords atrial fibrillation AND dabigatran OR rivaroxaban OR apixaban. The references identified from the literature review were then evaluated. All of the l...
متن کاملNovel therapeutic options for the emerging infectious diseases from Romania
Background The (re)emergence of certain infectious diseases in Romania, as the pathology treated in our Ward expressed it, include: the West Nile virus febrile diseases (mainly meningoencephalitis), the A (H1N1) pandemic influenza, malaria, amoebiasis, Clostridium difficile colitis. These infections were treated in our Ward as well, as presenting specific particularities of our specialty. As fa...
متن کاملNew uses for old drugs: Novel therapeutic options
Since decades, the rational discovery of new medicines has depended on the modification of molecular structures. Introducing a new drug to the market now costs an average of US$ 897 million which includes preclinical and clinical costs before the US FDA (Food and Drug Administration) approval and costs associated with studies conducted after a product has gained such approval. Moreover, the pro...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Frontiers in Immunology
سال: 2020
ISSN: 1664-3224
DOI: 10.3389/fimmu.2020.583853